A malignus melanoma molekuláris diagnosztikája: Molekuláris stádiummeghatározás, minimális reziduális betegség

Translated title of the contribution: Molecular diagnostics of malignant melanoma: Molecular staging, minimal residual disease

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Nucleic acid based molecular techniques have been introduced into the diagnosis of malignant melanoma similarly to other cancers. They were applied for refinement of staging and to detect minimal residual disease. There are several good melanocyte-specific genetic markers such as tyrosinase, gp100, Melan-A/MART-1 and MIA. Unlike in the case of the lymph nodes, peripheral blood or bone marrow do not contain melanocytes excluding the possibility of fals positive reactions. Considering the pronounced heterogenity of melanoma cells the most reliable molecular marker is the expression of tyrosinase. Several studies indicate that the quantity of circulating melanoma cells correlates with tumor burden and disease progression and reflects the effect of therapy. On the other hand, molecular techniques detect circulating melanoma cells much more frequently than the clinical manifestation of the disease progression (molecular recurrence), questioning the clinical significance of the detection of a small number of melanoma cells in the circulation. Based on these data molecular diagnostics is not part of the melanoma protocols yet and further studies are necessary to define its diagnostic role.

Original languageHungarian
Pages (from-to)63-66
Number of pages4
JournalMagyar Onkologia
Volume47
Issue number1
Publication statusPublished - 2003

Fingerprint

Molecular Pathology
Residual Neoplasm
Melanoma
Monophenol Monooxygenase
Melanocytes
Disease Progression
MART-1 Antigen
Tumor Burden
Genetic Markers
Nucleic Acids
Cell Count
Lymph Nodes
Bone Marrow
Recurrence
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{cff0e72e4a564ca292082cb8c96d9847,
title = "A malignus melanoma molekul{\'a}ris diagnosztik{\'a}ja: Molekul{\'a}ris st{\'a}diummeghat{\'a}roz{\'a}s, minim{\'a}lis rezidu{\'a}lis betegs{\'e}g",
abstract = "Nucleic acid based molecular techniques have been introduced into the diagnosis of malignant melanoma similarly to other cancers. They were applied for refinement of staging and to detect minimal residual disease. There are several good melanocyte-specific genetic markers such as tyrosinase, gp100, Melan-A/MART-1 and MIA. Unlike in the case of the lymph nodes, peripheral blood or bone marrow do not contain melanocytes excluding the possibility of fals positive reactions. Considering the pronounced heterogenity of melanoma cells the most reliable molecular marker is the expression of tyrosinase. Several studies indicate that the quantity of circulating melanoma cells correlates with tumor burden and disease progression and reflects the effect of therapy. On the other hand, molecular techniques detect circulating melanoma cells much more frequently than the clinical manifestation of the disease progression (molecular recurrence), questioning the clinical significance of the detection of a small number of melanoma cells in the circulation. Based on these data molecular diagnostics is not part of the melanoma protocols yet and further studies are necessary to define its diagnostic role.",
author = "J. T{\'i}m{\'a}r and O. Csuka",
year = "2003",
language = "Hungarian",
volume = "47",
pages = "63--66",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - A malignus melanoma molekuláris diagnosztikája

T2 - Molekuláris stádiummeghatározás, minimális reziduális betegség

AU - Tímár, J.

AU - Csuka, O.

PY - 2003

Y1 - 2003

N2 - Nucleic acid based molecular techniques have been introduced into the diagnosis of malignant melanoma similarly to other cancers. They were applied for refinement of staging and to detect minimal residual disease. There are several good melanocyte-specific genetic markers such as tyrosinase, gp100, Melan-A/MART-1 and MIA. Unlike in the case of the lymph nodes, peripheral blood or bone marrow do not contain melanocytes excluding the possibility of fals positive reactions. Considering the pronounced heterogenity of melanoma cells the most reliable molecular marker is the expression of tyrosinase. Several studies indicate that the quantity of circulating melanoma cells correlates with tumor burden and disease progression and reflects the effect of therapy. On the other hand, molecular techniques detect circulating melanoma cells much more frequently than the clinical manifestation of the disease progression (molecular recurrence), questioning the clinical significance of the detection of a small number of melanoma cells in the circulation. Based on these data molecular diagnostics is not part of the melanoma protocols yet and further studies are necessary to define its diagnostic role.

AB - Nucleic acid based molecular techniques have been introduced into the diagnosis of malignant melanoma similarly to other cancers. They were applied for refinement of staging and to detect minimal residual disease. There are several good melanocyte-specific genetic markers such as tyrosinase, gp100, Melan-A/MART-1 and MIA. Unlike in the case of the lymph nodes, peripheral blood or bone marrow do not contain melanocytes excluding the possibility of fals positive reactions. Considering the pronounced heterogenity of melanoma cells the most reliable molecular marker is the expression of tyrosinase. Several studies indicate that the quantity of circulating melanoma cells correlates with tumor burden and disease progression and reflects the effect of therapy. On the other hand, molecular techniques detect circulating melanoma cells much more frequently than the clinical manifestation of the disease progression (molecular recurrence), questioning the clinical significance of the detection of a small number of melanoma cells in the circulation. Based on these data molecular diagnostics is not part of the melanoma protocols yet and further studies are necessary to define its diagnostic role.

UR - http://www.scopus.com/inward/record.url?scp=0043203060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043203060&partnerID=8YFLogxK

M3 - Article

C2 - 12704457

AN - SCOPUS:0043203060

VL - 47

SP - 63

EP - 66

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 1

ER -